Daily Sepsis Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Mechanistic and translational advances dominate today’s sepsis literature: a phytochemical (dehydrocavidine) directly activates Nrf2 to suppress hepatocyte ferroptosis and ameliorate LPS-induced acute liver injury, and IgM-enriched IVIG normalizes sepsis-driven coagulation abnormalities in a large-animal model. Clinically, an NPC-focused meta-analysis of immune checkpoint inhibitor safety highlights sepsis as the leading cause of irAE-related death, underscoring the need for rigorous infection surveillance during immunotherapy.
Research Themes
- Ferroptosis and Nrf2 signaling in sepsis-induced organ injury
- Immunomodulatory correction of sepsis-associated coagulopathy
- Oncology immunotherapy safety: sepsis as a leading irAE fatality
Selected Articles
1. Dehydrocavidine alleviates lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway to inhibit hepatocyte ferroptosis.
Using in vivo LPS-induced rat SALI and in vitro cytokine-injured hepatocytes, the authors show that dehydrocavidine (DC) reduces liver injury and ferroptosis by directly binding Keap1 at R415 to liberate Nrf2, restoring redox balance and suppressing TNF-α/IFN-γ-driven mitochondrial dysfunction. These multimodal mechanistic data position Nrf2 activation and ferroptosis inhibition as promising strategies against Gram-negative sepsis-associated liver injury.
Impact: This study provides rigorous target engagement (Keap1 R415) and cross-platform validation linking ferroptosis to SALI mitigation, offering a druggable axis (Keap1–Nrf2) with translational potential.
Clinical Implications: While preclinical, the work supports Nrf2 activation and ferroptosis inhibition as therapeutic strategies for sepsis-related liver injury; DC or optimized derivatives warrant PK/PD, safety, and efficacy testing in clinically relevant sepsis models and early-phase trials.
Key Findings
- DC attenuated LPS-induced liver injury, microcirculatory disorder, and leukocyte adhesion in vivo.
- DC reduced hepatic ferroptosis under LPS challenge and corrected cytokine (TNF-α/IFN-γ)-induced mitochondrial abnormalities in hepatocytes.
- Mechanistically, DC bound Keap1 at R415, disrupted Keap1–Nrf2 complex formation, enabled Nrf2 nuclear translocation, and upregulated antioxidant genes.
Methodological Strengths
- Multi-modal mechanistic validation (ATAC-seq, CETSA, SPR, STED microscopy, molecular dynamics, site-directed mutagenesis).
- Integrated in vivo (rat SALI) and in vitro (HepG2 with cytokine injury) systems demonstrating target engagement and functional rescue.
Limitations
- Use of HepG2 cells and LPS rat model may not fully recapitulate human sepsis heterogeneity.
- Pharmacokinetics, toxicity, and optimal dosing of DC were not defined; off-target effects remain possible.
Future Directions: Evaluate DC (and analogs) in polymicrobial and clinically relevant sepsis models, conduct PK/PD and toxicology studies, test in primary human hepatocytes/organoids, and assess combinatorial strategies targeting ferroptosis and inflammatory signaling.
BACKGROUND: Sepsis-induced acute liver injury (SALI) remains a major challenge with limited effective treatments. Although Corydalis saxicola Bunting (CSB) exhibits anti-inflammatory and hepatoprotective properties, its role in SALI remains poorly understood. PURPOSE: To identify the active components and molecular mechanisms of CSB in protecting against SALI. METHODS: In vivo LPS-induced rat liver injury and in vitro cytokine-induced HepG2 injury models were established, treated with CSB extract or dehydrocavidine (DC). A series of advanced techniques including ferroptosis PCR array, super-resolution stimulated emission depletion (STED) microscopy, assay for transposase-accessible chromatin with sequencing (ATAC-seq), cellular thermal shift assay (CETSA), surface plasmon resonance (SPR), molecular dynamics simulation, and site-directed mutation were employed to investigate the underlying mechanisms. RESULTS: DC significantly mitigated LPS-induced liver injury, microcirculatory disorder, and leukocyte adhesion. It also alleviated liver ferroptosis under LPS challenge. In vitro studies revealed that LPS-activated macrophages secreted tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), which triggered hepatocyte ferroptosis. DC countered this process by inhibiting the production of these cytokines and correcting cytokine-induced mitochondrial abnormalities in hepatocytes. Mechanistically, DC bound to Kelch-like ECH-associated protein 1 (Keap1) at arginine 415 (R415), disrupting the formation of the Keap1/nuclear factor erythroid 2-related factor 2 (Nrf2) complex. This enabled Nrf2 nuclear translocation and promoted antioxidant gene expression, thereby correcting LPS-induced redox imbalance in hepatocytes. CONCLUSIONS: In addition to inhibiting LPS-induced macrophage activation, DC activates the Nrf2 signaling pathway in hepatocytes to alleviate inflammation-enhanced liver ferroptosis. It provides potential therapeutic strategies for sepsis and Gram-negative bacteria-associated liver injury.
2. IgM-enriched immunoglobulin treatment significantly improves coagulation dysbalance in an experimental animal model of fulminant sepsis.
In a porcine E. coli sepsis model, IgM-enriched IVIG normalized multiple coagulation disturbances: it reduced fibrinogen, shortened APTT, reversed pathological thrombin generation patterns (with and without exogenous triggers), and attenuated soluble P-selectin elevations. Simultaneous administration showed stronger effects than delayed dosing.
Impact: Provides large-animal evidence that targeted immunoglobulin therapy can modulate sepsis-associated coagulopathy, a key driver of organ failure and mortality.
Clinical Implications: Findings support testing IgM-enriched IVIG as an adjunct to correct coagulopathy in early fulminant sepsis, with an emphasis on timing. Clinical trials should assess dosing, safety, and endpoints including DIC resolution and organ support needs.
Key Findings
- Sepsis increased fibrinogen and prolonged APTT; IgM-IVIG significantly decreased fibrinogen and shortened APTT after E. coli.
- In TGA without exogenous triggers, sepsis increased ETP and peak thrombin; IgM-IVIG abolished these increases.
- In TGA with phospholipid/tissue factor, sepsis reduced ETP and peak thrombin; IgM-IVIG prevented these reductions.
- Soluble P-selectin elevations in sepsis were attenuated by simultaneous IgM-IVIG administration; simultaneous dosing outperformed delayed dosing.
Methodological Strengths
- Physiologically relevant large-animal (porcine) fulminant sepsis model.
- Comprehensive hemostasis profiling including coagulometry and dual-mode thrombin generation assays, plus platelet activation marker (soluble P-selectin).
Limitations
- Sample size not reported; survival and clinical endpoints were not assessed.
- Single-pathogen (E. coli) model limits generalizability; blinding/allocation concealment not described.
Future Directions: Randomized controlled trials in septic patients to test IgM-enriched IVIG for coagulopathy correction, exploring dose, timing, and effects on DIC, organ dysfunction, and mortality.
INTRODUCTION: Inflammation and coagulation are closely interrelated process in the pathogenesis of sepsis. In this study, we investigated whether intravenous IgM-enriched immunoglobulin (IgM-IVIG) preparation could improve hemostatic abnormalities in a fulminant sepsis model. MATERIALS AND METHODS: Live Escherichia coli (E.coli) bacteria were administered to pigs with simultaneously (E. coli + Ig) or delayed (E. coli post Ig) of IgM-IVIG while control pigs received only physiological saline. Prothrombin time, activated partial thromboplastin time (APTT) and fibrinogen were measured by coagulometry. Hematologic parameters and soluble P-selectin were also measured. Furthermore, thrombin generation assay was carried out by fluorimetry and results were evaluated by the Thrombinoscope software. RESULTS: In septic pigs continous increase of fibrinogen levels and significant prolongation of APTT were observed. However, IgM-IVIG treatment significantly decreased fibrinogen levels and shortened the APTT after E. coli administration. In addition, in thrombin generation assay (TGA), that was performed without any exogenous coagulation trigger a significant increase of endogenous thrombin potential (ETP) and peak thrombin were observed in the E. coli-administered group which were abolished by IgM-IVIG treatment. Furthermore, in another TGA using phospholipid and tissue factor triggers, a significant decrease of ETP and thrombin peak were detected in septic-group, however IgM-IVIG treatment prevented the effect of E. coli. Increased level of soluble P-selectin was measured in E. coli-administered group, but it was attenuted by simultaneously administered IgM-IVIG treatment. CONCLUSIONS: We conclude that IgM-IVIG attenuates sepsis-induced hemostatic abnormalities, and the effect of simultaneously administered IgM-IVIG was more pronounced.
3. Incidence and spectrum of immune-related adverse events in nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors.
Across 27 NPC trials of ICIs, all-grade irAEs were common (69.1%) but grade ≥3 events were less frequent (8.1%). Notably, among irAE-related deaths (n=17), sepsis was the most common cause, underscoring the need for infection vigilance and early sepsis recognition during immunotherapy.
Impact: Provides NPC-specific, PRISMA-adherent estimates of irAEs and identifies sepsis as the leading irAE-related cause of death, informing risk mitigation strategies in oncology practice.
Clinical Implications: Oncologists should implement structured infection surveillance and sepsis screening (e.g., early cultures, prompt antibiotics when indicated) during ICIs in NPC, alongside endocrine and pulmonary monitoring, to balance efficacy and safety.
Key Findings
- Pooled all-grade irAE incidence was 69.1% (95% CI, 50.4%-80.7%) across 2,296 patients.
- Grade ≥3 irAE incidence was 8.1% (95% CI, 6.1%-10.6%) across 2,459 patients.
- No significant differences in irAE incidence by disease stage, treatment line, or combination strategies.
- Among 17 irAE-related deaths, sepsis was the most common cause, followed by pneumonitis.
Methodological Strengths
- PROSPERO-registered, PRISMA-adherent systematic review and meta-analysis.
- NPC-specific synthesis across 27 clinical trials, enabling tailored safety inferences.
Limitations
- Heterogeneity and reporting biases across trials; lack of patient-level data limits subgroup analyses.
- Causality and attribution between infection-related sepsis versus immune-mediated toxicity cannot be fully disentangled.
Future Directions: Prospective, harmonized AE reporting with infection-specific endpoints in NPC ICI trials; studies to define sepsis risk factors, prophylaxis strategies, and early warning systems during immunotherapy.
BACKGROUND: Nasopharyngeal carcinoma (NPC), endemic to Southern China and Southeast Asia, presents significant clinical challenges. Immune checkpoint inhibitors (ICIs) have transformed NPC treatment but carry risks of immune-related adverse events (irAEs). Existing meta-analyses lack NPC-specific data, hindering targeted safety guidance. METHODS: This systematic review and meta-analysis, registered with PROSPERO (CRD420251003062), followed PRISMA guidelines. We searched PubMed, Embase, and Web of Science up to March 31, 2025, including all registered clinical trials of ICIs in NPC patients reporting irAEs. FINDINGS: A total of 27 clinical trials were included in the meta-analysis. The pooled incidence of all-grade irAEs in 2,296 patients was 69.1% (95% confidence interval [CI], 50.4%-80.7%), and that of grade 3 or higher irAE in 2,459 patients was 8.1% (95% CI, 6.1%-10.6%). Subgroup analyses revealed that there were no significant differences in the incidence of irAEs based on disease stages, lines of treatment, and combination treatment strategies. The main types of all-grade irAEs with an incidence rate greater than 1% are as follows: hypothyroidism (22.4%), rash (10.7%), pruritus (3.6%), increased aspartate aminotransferase (1.9%), increased alanine aminotransferase (1.8%), fatigue (1.6%), anemia (1.6%), pneumonia (1.5%), and hyperthyroidism (1.0%). A total of 17 patients died due to irAEs. Among these, sepsis was the most common cause of death, followed by pneumonitis. CONCLUSIONS: This meta-analysis provides a comprehensive overview of irAEs in NPC patients treated with ICIs. These NPC-specific data emphasize the importance of vigilant monitoring for endocrine, cutaneous, and severe pulmonary or infectious complications to balance the efficacy and safety of ICIs. FUNDING: Young Talent Program of Heyuan People's Hospital.